1. Home
  2. ACET vs BDL Comparison

ACET vs BDL Comparison

Compare ACET & BDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.06

Market Cap

79.9M

Sector

Health Care

ML Signal

HOLD

Logo Flanigan's Enterprises Inc.

BDL

Flanigan's Enterprises Inc.

HOLD

Current Price

$37.94

Market Cap

83.3M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACET
BDL
Founded
1947
1959
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
79.9M
83.3M
IPO Year
2017
1995

Fundamental Metrics

Financial Performance
Metric
ACET
BDL
Price
$8.06
$37.94
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$48.33
N/A
AVG Volume (30 Days)
89.0K
26.3K
Earning Date
05-06-2026
05-18-2026
Dividend Yield
N/A
1.90%
EPS Growth
N/A
49.72
EPS
N/A
1.98
Revenue
N/A
$205,248,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$19.92
Revenue Growth
N/A
8.99
52 Week Low
$0.46
$26.33
52 Week High
$9.47
$47.99

Technical Indicators

Market Signals
Indicator
ACET
BDL
Relative Strength Index (RSI) 47.62 43.91
Support Level $7.78 $29.15
Resistance Level $8.68 $38.32
Average True Range (ATR) 0.51 3.02
MACD -0.08 -0.82
Stochastic Oscillator 26.03 11.25

Price Performance

Historical Comparison
ACET
BDL

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

About BDL Flanigan's Enterprises Inc.

Flanigan'S Enterprises Inc operates as a chain of small cocktail lounges and packages liquor stores throughout South Florida. The business activity is principally conducted in two segments namely Restaurant and Package liquor store segment. Its Restaurant segment offers alcoholic beverages and full food service, and Package stores consist of retail liquor sales and related items. Its menu consists of a wide variety of options including prime rib, steaks, pasta, entree salads, burgers, a variety of sandwiches, and oversized signature desserts. The company generates maximum revenue from Restaurant segment.

Share on Social Networks: